热门资讯> 正文

Organon将以12亿美元收购Dermavant

2024-09-18 19:44

Organon (NYSE:OGN) said it will acquire Dermavant, which is a Roivant (ROIV) for $1.2 billion.
The consideration has an upfront payment of $175 million and a $75 million milestone payment upon regulatory approval, as well as payments of up to $950 million for the achievements of certain commercial milestones.
Additionally, the firm will pay Dermavant shareholders tiered royalties on net sales.

More on Organon

Organon & Co.: Cheap With Caveats
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
Eli Lilly, Organon expand distribution deal for migraine drug

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。